DE69512940D1 - N-hydroxy-harnstoff-derivate als entzündunghemmende mittel - Google Patents

N-hydroxy-harnstoff-derivate als entzündunghemmende mittel

Info

Publication number
DE69512940D1
DE69512940D1 DE69512940T DE69512940T DE69512940D1 DE 69512940 D1 DE69512940 D1 DE 69512940D1 DE 69512940 T DE69512940 T DE 69512940T DE 69512940 T DE69512940 T DE 69512940T DE 69512940 D1 DE69512940 D1 DE 69512940D1
Authority
DE
Germany
Prior art keywords
pct
inflammatory
hydroxy
resistant agent
urea derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69512940T
Other languages
English (en)
Other versions
DE69512940T2 (de
Inventor
Akemi Ando
Rodney Stevens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of DE69512940D1 publication Critical patent/DE69512940D1/de
Application granted granted Critical
Publication of DE69512940T2 publication Critical patent/DE69512940T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69512940T 1994-05-19 1995-06-07 N-hydroxy-harnstoff-derivate als entzündunghemmende mittel Expired - Fee Related DE69512940T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP12810594A JP3179286B2 (ja) 1994-05-19 1994-05-19 Ｎ−ヒドロキシ尿素系抗炎症剤
PCT/JP1995/001127 WO1996040659A1 (en) 1994-05-19 1995-06-07 N-hydroxyureas as antiinflammatory agents
CA002223023A CA2223023C (en) 1994-05-19 1995-06-07 N-hydroxyureas as antiinflammatory agents

Publications (2)

Publication Number Publication Date
DE69512940D1 true DE69512940D1 (de) 1999-11-25
DE69512940T2 DE69512940T2 (de) 2000-02-17

Family

ID=27170556

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69512940T Expired - Fee Related DE69512940T2 (de) 1994-05-19 1995-06-07 N-hydroxy-harnstoff-derivate als entzündunghemmende mittel

Country Status (19)

Country Link
US (1) US5814648A (de)
EP (1) EP0832078B1 (de)
JP (2) JP3179286B2 (de)
AT (1) ATE185803T1 (de)
AU (1) AU705505B2 (de)
BR (1) BR9502072A (de)
CA (1) CA2223023C (de)
CZ (1) CZ286331B6 (de)
DE (1) DE69512940T2 (de)
DK (1) DK0832078T3 (de)
ES (1) ES2138211T3 (de)
FI (1) FI974444A (de)
GR (1) GR3032301T3 (de)
HU (1) HUT77950A (de)
IL (1) IL113706A (de)
NO (1) NO310288B1 (de)
NZ (1) NZ287551A (de)
PL (1) PL179853B1 (de)
WO (1) WO1996040659A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19548419A1 (de) * 1995-12-22 1997-06-26 Bayer Ag Substituierte Thiazoline
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
EP1866293A1 (de) 2005-03-31 2007-12-19 UCB Pharma, S.A. Eine oxazol- oder thiazolgruppe enthaltende verbindungen, verfahren zu deren herstellung und ihre anwendungen
EP2392258B1 (de) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-Informatiksystem
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
WO2010129819A2 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
WO2021214048A1 (en) * 2020-04-20 2021-10-28 Johann Wolfgang Goethe-Universität Frankfurt am Main Dual inhibitors of soluble epoxide hydrolase and 5-lipoxygenase

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0540673T3 (da) * 1990-07-25 1997-03-24 Abbott Lab Acetylen-derivater med lipoxygenaseinhiberende virkning
JP2528741B2 (ja) * 1991-01-09 1996-08-28 ファイザー製薬株式会社 オキサゾ―ル、チアゾ―ルおよびイミダゾ―ル化合物
JPH07100687B2 (ja) * 1991-06-13 1995-11-01 ファイザー製薬株式会社 新規なｎ−ヒドロキシ尿素化合物および組成物
US5288751A (en) * 1992-11-06 1994-02-22 Abbott Laboratories [(Substituted) phenyalkyl]furylalkynyl-and [substituted) phenyalkyl] thienylalkynyl-N-hydroxyurea inhibitors or leukotriene biosynthesis
DE69411003T2 (de) * 1993-04-07 1998-10-08 Pfizer Inc., New York, N.Y. Cycloalkylhydroxyharnstoffe und ihre verwendung als lipoxy-genase-inhibitoren

Also Published As

Publication number Publication date
CA2223023A1 (en) 1996-12-19
ATE185803T1 (de) 1999-11-15
NZ287551A (en) 1999-02-25
BR9502072A (pt) 1996-04-09
WO1996040659A1 (en) 1996-12-19
PL324012A1 (en) 1998-04-27
DK0832078T3 (da) 2000-04-25
MX9709986A (es) 1998-03-29
CZ382497A3 (cs) 1999-03-17
IL113706A0 (en) 1995-08-31
US5814648A (en) 1998-09-29
FI974444A (fi) 1998-02-04
JPH10506649A (ja) 1998-06-30
JPH07309849A (ja) 1995-11-28
NO975726D0 (no) 1997-12-05
CZ286331B6 (cs) 2000-03-15
JP3179286B2 (ja) 2001-06-25
IL113706A (en) 1999-08-17
AU2629495A (en) 1996-12-30
NO975726L (no) 1998-02-03
NO310288B1 (no) 2001-06-18
EP0832078A1 (de) 1998-04-01
GR3032301T3 (en) 2000-04-27
CA2223023C (en) 2001-07-17
AU705505B2 (en) 1999-05-27
HUT77950A (hu) 1998-12-28
PL179853B1 (pl) 2000-11-30
FI974444A0 (fi) 1997-12-05
EP0832078B1 (de) 1999-10-20
DE69512940T2 (de) 2000-02-17
ES2138211T3 (es) 2000-01-01

Similar Documents

Publication Publication Date Title
TW262461B (de)
ATE206123T1 (de) Phenylxanthin-derivate
DE69512940D1 (de) N-hydroxy-harnstoff-derivate als entzündunghemmende mittel
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung
FI932654A0 (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
DE69413831D1 (de) Phenoxyphenylcyclopentenyl-hydroxyharnstoffe
ATE190845T1 (de) Rektale flunisolid-zubereitung zur behandlung entzündlicher darmerkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee